>
♥

FibroScan Interpretation Guide

Understand your FibroScan (Transient Elastography) results. Based on EASL guidelines and international standards.

Interpret Your FibroScan Results

What You Need: Your liver stiffness measurement (in kPa) from your FibroScan report. CAP score is optional.

Normal range: 2.5-6.0 kPa

CAP measures liver fat content (steatosis)

What is FibroScan?

FibroScan (Transient Elastography) is a non-invasive ultrasound-based test that measures liver stiffness, which indicates the amount of scarring (fibrosis).

Fibrosis Stages

F0-F1: < 7.0 kPa

F2: 7.0-9.6 kPa

F3: 9.6-12.5 kPa

F4: > 12.5 kPa

Understanding FibroScan in Simple Terms

How Does FibroScan Work?

FibroScan uses sound waves to measure how stiff your liver is. A stiffer liver usually means more scarring (fibrosis).

The Test:

  • ✓ Non-invasive (no needles or surgery)
  • ✓ Takes about 5-10 minutes
  • ✓ No pain or discomfort
  • ✓ Can be done in outpatient clinic

What is CAP Score?

CAP (Controlled Attenuation Parameter) measures the amount of fat in your liver (steatosis). It's measured during the same FibroScan test.

CAP Ranges:

  • • < 100 dB/m: No steatosis
  • • 100-150 dB/m: Mild (S1)
  • • 150-200 dB/m: Moderate (S2)
  • • > 200 dB/m: Severe (S3)

When is FibroScan Recommended?

  • ✓ Intermediate FIB-4 score (1.30-2.67)
  • ✓ Suspected advanced fibrosis
  • ✓ Monitoring treatment response
  • ✓ Screening for cirrhosis
  • ✓ Patients with chronic liver disease

Clinical Guidelines & References

EASL Guidelines (2016)

European Association for the Study of the Liver recommends transient elastography as a non-invasive method for assessing liver fibrosis in patients with NAFLD.

Reference: EASL Clinical Practice Guidelines: Management of hepatic encephalopathy. J Hepatol. 2014;60(3):715-735.

AASLD Guidelines (2020)

American Association for the Study of Liver Diseases endorses transient elastography as a reliable tool for non-invasive assessment of liver fibrosis.

Reference: Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):328-357.

Sandrin et al. Validation Study (2003)

Original validation study demonstrating the accuracy of transient elastography in assessing liver fibrosis stages.

Reference: Sandrin L, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713.

Sasso et al. CAP Validation (2010)

Study validating CAP (Controlled Attenuation Parameter) for non-invasive assessment of hepatic steatosis.

Reference: Sasso M, et al. Controlled attenuation parameter (CAP): a novel VCTE-derived parameter for the assessment of hepatic steatosis. J Hepatol. 2012;56(6):1312-1319.

Disclaimer: This guide is for educational purposes only. It is not a substitute for professional medical advice. Always consult with your healthcare provider to interpret your FibroScan results and determine the appropriate treatment plan.